The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer

This article shall describe the role of (18)F-Sodium Fluoride ((18)F-NaF) PET/CT bone scanning in the staging of breast and prostate cancer. (18)F-NaF PET was initially utilised as a bone scanning agent in the 1960s and early 1970s, however its usage was restricted by the then available gamma cameras. The advent of hybrid PET/CT cameras in the late 1990s has shown a resurgence of interest in its usage and role. After a brief introduction, this paper will describe the radiopharmaceutical properties, dosimetry, pharmacokinetics, and mechanism of uptake of (18)F-NaF. The performance of (18)F-NaF PET/CT is then compared with conventional bone scintigraphy utilizing current evidence from the literature. Strengths and weaknesses of (18)F-NaF PET/CT imaging shall be highlighted. Clinical examples of improved accuracy of diagnosis and impact on patient management shall be illustrated. Limitations of (18)F-NaF PET/CT imaging will be outlined.

Journal of nuclear medicine technology. 2016 Sep 15 [Epub ahead of print]

Randeep Kulshrestha, Sobhan Vinjamuri, Andrew England, Julie Nightingale, Peter Hogg

Queensland X-ray, Australia;, Royal Liverpool Hospital, United Kingdom;, University of Salford, United Kingdom.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.